AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06416735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours
Study NCT02066623 — intervention group
Intervention type: DEVICE
Intervention: ABSORB Scaffold
Description: Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
Study NCT03471936 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Acquisition of pressure-volume-loops
Description: Diagnostic workup including cardiac MRI, Echocardiography and cardiopulmonary exercise test (CPET) followed by invasive acquisition of RV and left ventricular (LV) pressure-volume-loops
Study NCT02061605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Tissue Welding Device
Description: Laparoscopic partial nephrectomy will be robotically assisted using the second generation da Vinci® Surgical System. Once the tumor is resected with laparoscopic scissors with a margin of healthy tissue, the solder will be dripped onto the cut surface of the parenchyma. A laparoscopic rigid 5mm spot-size laser hand-piece will be passed through the 10-mm port. The diode laser will be then used to weld a thin layer of solder onto the cut parenchymal surface. The 60 Watt 810-nm diode laser will be set to deliver continuous energy. During soldering, the tip of the laparoscopic laser hand-piece will be maintained 1 to 2 cm from the renal surface to generate a spot size of approximately 5 mm. Each spot will be treated with the laser until the color of the solder changes from green to white. The renal pedicle clamp will be removed to allow renal blood supply to be restored and the surgical site inspected for evidence of bleeding for 10 minutes prior to completing the surgical procedure.
Study NCT02032602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Dry Needling
Study NCT02032602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Dry Needling
Study NCT04714528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: Physical exercise as described before.
Study NCT04714528 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Relaxation Therapy
Description: Relaxation therapy as described before.
Study NCT03640468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine full dose
Description: This group will receive induction of anesthesia using Ketamine 1 mg/Kg
Study NCT03640468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine half dose
Description: This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg
Study NCT03640468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: This group will receive lidocaince 1 mg/Kg
Study NCT03640468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: This group will receive midazolam 0.05 mg/Kg
Study NCT03640468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: This group will receive midazolam 0.05 mg/Kg
Study NCT03640468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: This group will receive normal saline 10 mL
Study NCT02693782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 g/day maltodextrin in 3 portions of 5 g.
Study NCT02693782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fibre supplement
Description: 15 g/day Wheat Bran Extract in 3 portions of 5 g.
Study NCT04564144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine Hydrochloride
Description: A study will be conducted on the three tested orodispersible tablets and the commercial one (control). 6 volunteers are asked to cease any medication 7 days prior to blood sampling at least. Each volunteer will undergo 4 study sessions with one week of washout period in between (cross-overed to receive the other formulation). All volunteers are asked to fast overnight before taking the tablet. The tablet should be kept for 10 min in the mouth before swallowing without water. Just before taking the tablet, three milliliters of venous blood samples will be drown (predose, 0 h) and at 30, 60, 90, 120, 240, 360, 480, 720 min and 24 h postdose and stored in tubes coated with sodium heparin. Separation of plasma from Blood samples will be carried out by centrifuging at 5000 rpm for 10 min, then, it will be frozen at -20°C until analysis. By employing high-performance liquid chromatography (HPLC), the plasma concentration of MCZ will be assayed
Study NCT02690220 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TiLOOP® PRO Plus A
Description: The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.
Study NCT03635814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YD312 50mg
Description: YD312 50mg \* 1 + placebo 6 tablets
Study NCT03635814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YD312 150mg
Description: YD312 50mg \* 3 + placebo 6 tablets
Study NCT03635814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YD312 350mg
Description: YD312 50mg \* 7 tablets
Study NCT03635814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: YD312 0mg \* 7 tabets
Study NCT04635566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
Description: mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
Study NCT04635566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one time/day at the evening.
Study NCT01132612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A 150 mg powder for solution
Study NCT01132612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to AIN457A 150 mg powder for solution
Study NCT03610399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Different total dose and supervision.
Study NCT03610399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Primaquine
Description: Different total dose and supervision.
Study NCT02252536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin enacarbil
Description: Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
Study NCT02252536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
Study NCT04048590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skilled Nursing Facility at Home
Description: We plan to deploy an innovative and tailored set of rehabilitation services delivered in a patient's home that would allow for discharge from the hospital directly to home, despite the need for more intensive rehabilitative care not currently found in the home setting. We plan to combine a high-touch and high-tech approach that combines novel uses of personnel practicing at the very top of their license with novel uses of technology.
Study NCT04044183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Brains 1
Description: Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal \& coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
Study NCT04044183 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Brains 1
Description: Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal \& coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
Study NCT04044183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Brains 2
Description: This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition.
Study NCT04044183 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Brains 2
Description: This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition.
Study NCT02941874 — intervention group
Intervention type: OTHER
Intervention: Blood sample collection during an OGTT to assess IRAP blood concentration
Description: Blood sample collection during an OGTT to assess IRAP blood concentration. Blood samples will be collected every 15 minutes during 3 hours
Study NCT04060563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSPIRSTAR IS02 MICROCURRENT STIMULATOR
Description: Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes.
Study NCT04060563 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: INSPIRSTAR IS02 MICROCURRENT STIMULATOR
Description: Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes.
Study NCT04351763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Ion channel blocker
Study NCT04351763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Ion channel blocker
Study NCT02676388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freeze-dried, Capsulized FMT
Study NCT02676388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fresh FMT
Study NCT04720404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Participants in the intervention group will follow a 4-week adapted MBSR training. The training consists of biweekly sessions of 1,5 hours. The training is structured based on the Mindfulness-Based Stress Reduction training as originally designed by John Kabat Zinn. The program includes both formal and informal meditation exercises.
Study NCT04720404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help mindfulness/compassion exercises
Description: Participants in the self-help group will receive a 4-week program with daily suggestions for mindfulness/compassion exercises of 30 minutes on a YouTube-channel. Participants can schedule the exercises themselves.
Study NCT04720404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support as usual
Description: Support as usual (SAU) consists of facilities or interventions already available healthcare organisations provided to their healthcare workers (e.g. buddy-, team- and peer support system, shopping/dinner service etc.).
Study NCT04720404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support as usual
Description: Support as usual (SAU) consists of facilities or interventions already available healthcare organisations provided to their healthcare workers (e.g. buddy-, team- and peer support system, shopping/dinner service etc.).
Study NCT01159613 — intervention group
Intervention type: OTHER
Intervention: Responders
Description: Responders
Study NCT01159613 — intervention group
Intervention type: OTHER
Intervention: Non Responders
Description: Non Responders
Study NCT01936909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (weeks 1-2)
Description: Anakinra 100 mg daily for weeks 1 and 2
Study NCT01936909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (weeks 3-12)
Study NCT01936909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04611854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guidance
Description: Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
Study NCT04611854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICBT for alcohol misuse
Description: The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 8 lessons distributed across 8 weeks.
Study NCT04611854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT for alcohol misuse
Description: The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 8 lessons distributed across 8 weeks.
Study NCT03864445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: oral administration
Study NCT03864445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebp
Description: oral administration
Study NCT02914054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose Dexamethasone pulses
Description: In HD-DXM arm, DXM was administered intravenously at 40 mg in 500cc normal saline (0.9% saline) during 1 hour for consecutive 4 days and then stopped. This cycle was repeated in 14 days interval to receive 3 cycles of treatment.
Study NCT02914054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Patients in PDN arm received PDN orally at 1.0 mg/kg body weight daily for 4 consecutive weeks. After achieving responses the medication tapered gradually to less than 15mg daily or terminated over 4-6 weeks aimed at maintaining platelet count over 30 ×109/L.
Study NCT00619528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Description: Intervention: a four-dose (peri-operative and 3, 6, and 9-month boost) DHSC infusion protocol using two-dose Campath-1H induction combined with transient (conditioning) Tacrolimus/Sirolimus and MMF therapy will result in a high degree of macro-chimerism (>10%), and a robust prolonged donor-specific (post-thymic) immunoregulatory condition that will allow renal transplant survival in the absence of permanent immunosuppression.
Study NCT03627897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: The erector spinae plane blocks proceed with 0,5 ml/kg of 0,25% bupivacain (Group B).
Study NCT03627897 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: saline
Description: No drugs or interventions were administered to the control group.
Study NCT02648516 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional plus AAIT
Description: Participants will receive ART and taken i.v., at a dose of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
Study NCT02104154 — intervention group
Intervention type: DEVICE
Intervention: Samsung LABGEO PT10 Hepatic Panel
Study NCT01921855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY Factor VII (BAY86-6150)
Description: BAY Factor VII (BAY86-6150), 6.5 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
Study NCT01921855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY Factor VII (BAY86-6150)
Description: BAY Factor VII (BAY86-6150), 20 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
Study NCT01921855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY Factor VII (BAY86-6150)
Description: BAY Factor VII (BAY86-6150), 50 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
Study NCT01921855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY Factor VII (BAY86-6150)
Description: BAY Factor VII (BAY86-6150), 90 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
Study NCT01921855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
Study NCT00224094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin® (oral) vs. Alora® (transdermal)
Study NCT02679599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B-MOBILE-CARDIAC smartphone application
Study NCT02679599 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cardiac rehabilitation as usual
Study NCT02679599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation as usual
Study NCT01115842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 4000IU per day for 5 days
Study NCT03526887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, Q3W
Study NCT02933736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Study NCT04128345 — intervention group
Intervention type: DEVICE
Intervention: Use of navigation system
Description: Feasibility assessment of using an integrated navigation system incorporating advanced diffusion MRI, volumentric tumour representation and intraoperative ultrasound
Study NCT01824680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: There is two sequences, one before and one after the physical activity program. Each sequence contains one rest session and one exercise session
Study NCT04677699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Combined Risk Score
Description: Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.
Study NCT01460186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)
Description: Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.
Study NCT01448239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:Solution Route of administration: Subcutaneous
Study NCT02634203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Pulmonary Angioplasty (BPA)
Description: Balloon pulmonary angioplasty (BPA) will be done via femoral vein. 2 sessions will be performed during the same hospitalization following by additional sessions at an interval of 2-3 weeks until a mean PAP\< 30 mmHg is achieved A pulmonary angiography and a right heart catheterization will be performed at each BPA session